Who Should Receive T-DXd First Line? Which patients are best suited for a T-DXd-based first-line approach? This discussion explores symptom burden, neuropathy concerns, complete response rates, and why earlier use of the most effective therapy may offer the greatest benefit. FacebookXRedditPinterestEmail You may also like Video DESTINY-Breast09 & the Future of Care – Dr. Irene Kang & Dr. Aditya Bardia 1 min read Video Why First-Line Therapy Matters in HER2+ Metastatic Breast Cancer 1 min read Video DESTINY-Breast09: Nearly 4 Years of PFS with T-DXd 1 min read Video Managing Risk vs Benefit with T-DXd 1 min read Video Dose Optimization: The Secret to Long-Term T-DXd Success 1 min read Video Monitoring ILD with T-DXd: What Clinicians Need to Know 1 min read Recommended Videos DESTINY-Breast11, DESTINY-Breast05 & What Comes Next – Dr. Neil Iyengar & Dr. Komal Jhaveri 4 months ago Rethinking First-Line Metastatic HER2+ Therapy with T-DXd – Drs. Mouabbi, O’Shaughnessy & Rimawi 4 months ago Rewriting Neoadjuvant & Adjuvant HER2+ Breast Cancer Strategy -Drs. Alison Conlin & Heather McArthur 4 months ago Is HER2+ Metastatic Breast Cancer Curable? What Comes Next – Dr. Gregory Vidal & Dr. Nusayba Bagegni 4 months ago
DESTINY-Breast11, DESTINY-Breast05 & What Comes Next – Dr. Neil Iyengar & Dr. Komal Jhaveri 4 months ago
Rethinking First-Line Metastatic HER2+ Therapy with T-DXd – Drs. Mouabbi, O’Shaughnessy & Rimawi 4 months ago
Rewriting Neoadjuvant & Adjuvant HER2+ Breast Cancer Strategy -Drs. Alison Conlin & Heather McArthur 4 months ago
Is HER2+ Metastatic Breast Cancer Curable? What Comes Next – Dr. Gregory Vidal & Dr. Nusayba Bagegni 4 months ago